Related Experiment Video
Updated: Aug 22, 2026

Measuring Single-Cell Mitochondrial DNA Copy Number and Heteroplasmy Using Digital Droplet Polymerase Chain Reaction
Published on: July 12, 2022
Platelets, a typical source of error in real-time PCR quantification of mitochondrial DNA content in human peripheral
Brigitte Banas1, B P Kost, F D Goebel
1Department of Infectious Diseases, Medical Policlinic, Ludwig-Maximilian-University München, Germany. brigitte.banas@ukb.uni-bonn.de
Abstract:
Nucleoside analogues can induce toxic effects on mitochondria by inhibiting the human DNA polymerase-gamma. The clinically observed toxicities can range from slightly increased serum lactate levels to potentially severe and fatal lactic acidosis. A growing interest exists for detection of changes in mitochondrial (mt) DNA content in patients receiving antiretroviral therapy (HAART). Most studies use peripheral blood mononuclear cell (PBMC) fractions to investigate mt DNA content via Real-Time PCR in patients, not accounting platelets falsifying the mitochondrial (mt)DNA:nuclear (n)DNA-ratio. In this study we suggest a procedure to eliminate disturbing platelets totally. 8 healthy controls (G1), 6 therapy-naive HIV-infected patients (G2) and 9 HIV-infected patients under HAART (G3) were examined for mtDNA:nDNA-ratio using Real-Time PCR technology. Different blood collection and/or PBMC isolation strategies were analysed for variances of outcome at examinations of the same blood donor. Using DNA prepared of whole blood specimens, mtDNA:nDNA-ratios showed no differences in all investigated groups (G1, G2, G3). Comparing mtDNA:nDNA-ratios of platelet-depleted PBMC fractions of G1 with G2 revealed a reduction of 22% (p = 0.128) and a steeper reduction of 40% (p = 0.0036) comparing specimens of G1 with G3. Scrutinising differently processed specimens within the groups themselves, in G2 whole blood versus platelet-containing PBMC specimens showed a difference in mtDNA:nDNA-ratios of 26% (p = 0.0406), whereas a comparison of whole blood versus platelet-free PBMC specimens led to a comparatively more distinct reduction of 35% (p = 0.0089). The same effect was seen in G3, where whole blood versus platelet-containing PBMC specimens revealed a reduction of 32% (p = 0.01) and whole blood versus platelet-free PBMC specimens showed a 42% (p = 0.0011) decrease. Furthermore analysing each single patient in relation to the different methods, a minor fluctuation margin could be found using platelet-free PBMC specimens for Real-Time PCR. Using platelet-free PBMCs for mt DNA content detection, a correlation of low mtDNA:nDNA-ratios to clinical signs, like elevated lactate levels or lipodystrophy, could be observed. Light-microscopic evaluation for platelets, comparing platelet-containing PBMC fractions versus platelet-depleted PBMC fractions reinforced the Real-Time PCR results. Our data demonstrate that the first step of the blood sample collection/preparation is critical for valid illustration of mt DNA content in HIV-infected patients using ultra-sensitive Real-Time PCR technology. The use of serum tubes for blood collection is an easy and low-cost alternative to expensive cell sorting for elimination of disturbing platelets. Using platelet-free PBMC fractions for measurement mt DNA content could be a surrogate marker for clinical signs mediated by HAART.
Insights
Platelets can falsely alter mitochondrial DNA measurements in HIV patients on HAART. Removing platelets from blood samples ensures accurate detection of mitochondrial DNA changes, correlating with clinical signs.
Area of Science:
- Molecular Biology
- Virology
- Genetics
Background:
- Nucleoside analogues in HAART can cause mitochondrial toxicity by inhibiting DNA polymerase-gamma.
- Clinical toxicities include elevated lactate levels and lactic acidosis.
- Accurate measurement of mitochondrial DNA (mtDNA) content is crucial for monitoring HAART-related toxicity.
Purpose of the Study:
- To develop and validate a method for accurate mtDNA:nDNA ratio determination in HIV patients.
- To investigate the impact of platelets on mtDNA content measurements using Real-Time PCR.
- To establish a reliable surrogate marker for HAART-mediated clinical signs.
Main Methods:
- Collected blood samples from healthy controls (G1), therapy-naive HIV patients (G2), and HAART-treated HIV patients (G3).
- Compared mtDNA:nDNA ratios using Real-Time PCR in whole blood, platelet-containing PBMCs, and platelet-free PBMCs.
- Utilized light microscopy to confirm platelet removal from PBMC fractions.
Main Results:
- Platelets significantly falsify mtDNA:nDNA ratios in peripheral blood mononuclear cell (PBMC) fractions.
- Platelet-free PBMCs demonstrated a significant reduction in mtDNA:nDNA ratios compared to whole blood in G2 and G3.
- Low mtDNA:nDNA ratios in platelet-free PBMCs correlated with clinical signs like elevated lactate and lipodystrophy.
Conclusions:
- Accurate mtDNA content assessment in HIV patients requires meticulous sample preparation to eliminate platelets.
- Using platelet-free PBMCs for mtDNA:nDNA ratio measurement provides a valid and sensitive marker for HAART toxicity.
- Serum tubes offer a cost-effective alternative for sample collection, preventing platelet contamination.

